| Year |
Citation |
Score |
| 2022 |
Hall BJ, Bhojwani AA, Wong H, Law A, Flint H, Ahmed E, Innes H, Cliff J, Malik Z, O'Hagan JE, Hall A, Sripadam R, Tolan S, Ali Z, Hart C, ... ... Mehta S, et al. Neoadjuvant Trastuzumab and Pertuzumab for Early HER2-Positive Breast Cancer: A Real World Experience. The Breast Journal. 2022: 7146172. PMID 35833190 DOI: 10.1155/2022/7146172 |
0.454 |
|
| 2019 |
Ali A, Song YP, Mehta S, Mistry H, Conroy R, Coyle C, Logue J, Tran A, Wylie J, Janjua T, Joseph L, Joseph J, Choudhury A. Palliative radiotherapy in bladder cancer - importance of patient selection: A retrospective multicenter study. International Journal of Radiation Oncology, Biology, Physics. PMID 31283979 DOI: 10.1016/j.ijrobp.2019.06.2541 |
0.316 |
|
| 2016 |
Mehta S, Illidge T, Choudhury A. Immunotherapy with radiotherapy in urological malignancies. Current Opinion in Urology. PMID 27552139 DOI: 10.1097/MOU.0000000000000335 |
0.392 |
|
| 2011 |
Mehta S, Hughes NP, Buffa FM, Li SP, Adams RF, Adwani A, Taylor NJ, Levitt NC, Padhani AR, Makris A, Harris AL. Assessing early therapeutic response to bevacizumab in primary breast cancer using magnetic resonance imaging and gene expression profiles. Journal of the National Cancer Institute. Monographs. 2011: 71-4. PMID 22043045 DOI: 10.1093/jncimonographs/lgr027 |
0.547 |
|
| 2010 |
Azam F, Mehta S, Harris AL. Mechanisms of resistance to antiangiogenesis therapy. European Journal of Cancer (Oxford, England : 1990). 46: 1323-32. PMID 20236818 DOI: 10.1016/j.ejca.2010.02.020 |
0.597 |
|
| Show low-probability matches. |